Treatment of botulism with 3,4-diaminopyridine phosphate
Abstract
3,4-diaminopyridine phosphate (3,4-DAP) is the first small-molecule to reverse toxic signs and pro ote survival after a lethal botulism challenge, as demonstrated in rodents (Vazquez- Cintron et al. 2020), non-human primates (DTRA-funded Battelle Study Number B05928) and clinical patients (Dock et al. 2002; Friggeri et al. 2013). To further evaluate the suitability of 3,4- DAP as a broad-spectrum treatment for botulism, we will compare the therapeutic effects of 3,4- DAP infusion on toxic signs and survival in rats lethally challenged with BoNT serotypes A, B, E or F. In addition, we will evaluate synergistic benefits of 3,4-DAP infusion in combination with HBAT treatment. At the completion of these studies, we will have characterized time- and dose- dependent effects of 3,4-DAP infusion, alone and in combination with HBAT treatment, following lethal botulism challenge in rodents. These studies will provide the foundation for advanced development of 3,4-DAP as a fieldable medical countermeasure for botulism poisoning.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 19, 2022
- Source ID
- HDTRA12210029
Entities
People
- Patrick M. McNutt
Organizations
- Defense Threat Reduction Agency
- Wake Forest University